Search research articles
Contact Us
Filters
Showing results (111-120 of 127) with videos related to
Page
of 13
Sort By:
Plos One
|
January 24, 2013
The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network
Caroline J Voskens, Simone M Goldinger, Carmen Loquai, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 4, 2019
Targeted Therapy in Advanced Melanoma With Rare <i>BRAF</i> Mutations
Christian Menzer, Alexander M Menzies, Matteo S Carlino, et al.
Journal for Immunotherapy of Cancer
|
February 4, 2025
Phase I study of intratumoral administration of CV8102 in patients with advanced melanoma, squamous cell carcinoma of the skin, squamous cell carcinoma of the head and neck, or adenoid cystic carcinoma
Thomas Eigentler, Ioannis Thomas, Igor Samoylenko, et al.
Nature Communications
|
March 14, 2020
Cancer immune control needs senescence induction by interferon-dependent cell cycle regulator pathways in tumours
Ellen Brenner, Barbara F Schörg, Fatima Ahmetlić, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 24, 2025
Targeted therapy for rare BRAF-mutated melanoma: Updated multicenter analysis and launch of a publicly accessible online outcome database
Christian Menzer, Susanne Dugas-Breit, Martin Dugas, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 23, 2024
The side effect registry immuno-oncology (SERIO) - A tool for systematic analysis of immunotherapy-induced side effects
Carolin Ertl, Theresa Ruf, Dirk Mentzer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 26, 2022
Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)
Jeffrey S Weber, Dirk Schadendorf, Michele Del Vecchio, et al.
Frontiers in Oncology
|
November 8, 2021
Grade 4 Neutropenia Secondary to Immune Checkpoint Inhibition - A Descriptive Observational Retrospective Multicenter Analysis
Anne Zaremba, Rafaela Kramer, Viola De Temple, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 18, 2021
Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition
Sarah Knispel, Maximilian Gassenmaier, Alexander M Menzies, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
|
October 16, 2023
S3 guideline "actinic keratosis and cutaneous squamous cell carcinoma"- update 2023, part 1: treatment of actinic keratosis, actinic cheilitis, cutaneous squamous cell carcinoma in situ (Bowen's disease), occupational disease and structures of care
Markus V Heppt, Ulrike Leiter, Theresa Steeb, et al.
Page
of 13
Search research articles
Search
Showing results (111-120 of 127) with videos related to
Sort By:
Page
of 13
Plos One
|
January 24, 2013
The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network
Caroline J Voskens, Simone M Goldinger, Carmen Loquai, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 4, 2019
Targeted Therapy in Advanced Melanoma With Rare <i>BRAF</i> Mutations
Christian Menzer, Alexander M Menzies, Matteo S Carlino, et al.
Journal for Immunotherapy of Cancer
|
February 4, 2025
Phase I study of intratumoral administration of CV8102 in patients with advanced melanoma, squamous cell carcinoma of the skin, squamous cell carcinoma of the head and neck, or adenoid cystic carcinoma
Thomas Eigentler, Ioannis Thomas, Igor Samoylenko, et al.
Nature Communications
|
March 14, 2020
Cancer immune control needs senescence induction by interferon-dependent cell cycle regulator pathways in tumours
Ellen Brenner, Barbara F Schörg, Fatima Ahmetlić, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 24, 2025
Targeted therapy for rare BRAF-mutated melanoma: Updated multicenter analysis and launch of a publicly accessible online outcome database
Christian Menzer, Susanne Dugas-Breit, Martin Dugas, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 23, 2024
The side effect registry immuno-oncology (SERIO) - A tool for systematic analysis of immunotherapy-induced side effects
Carolin Ertl, Theresa Ruf, Dirk Mentzer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 26, 2022
Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)
Jeffrey S Weber, Dirk Schadendorf, Michele Del Vecchio, et al.
Frontiers in Oncology
|
November 8, 2021
Grade 4 Neutropenia Secondary to Immune Checkpoint Inhibition - A Descriptive Observational Retrospective Multicenter Analysis
Anne Zaremba, Rafaela Kramer, Viola De Temple, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 18, 2021
Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition
Sarah Knispel, Maximilian Gassenmaier, Alexander M Menzies, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
|
October 16, 2023
S3 guideline "actinic keratosis and cutaneous squamous cell carcinoma"- update 2023, part 1: treatment of actinic keratosis, actinic cheilitis, cutaneous squamous cell carcinoma in situ (Bowen's disease), occupational disease and structures of care
Markus V Heppt, Ulrike Leiter, Theresa Steeb, et al.
Page
of 13